SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively re-rate the stock, shifting from viewing it as a cyclical memory play to an essential, long-term AI infrastructure backbone amid persistent DRAM and NAND supply shortages. The community is heavily focused on the stock's parabolic trajectory and potential for further multiple expansion, with many discussing the impact of structural supply bottlenecks and the broader memory supercycle through 2027.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is trending as investors bet on the companys specialized non-volatile MRAM as a critical component for emerging Edge AI and robotics infrastructure. The community is actively debating the stock's potential for a massive short squeeze due to its low float, while highlighting its strategic positioning in defense and aerospace supply chains.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, where alignment on submission plans for sonelokimab in hidradenitis suppurativa has effectively de-risked the regulatory path toward a September BLA filing. The community is actively debating the stock's potential for a lucrative buyout, citing analyst upgrades and comparing the nanobody's efficacy and best-in-class label potential against existing market competitors.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending as investors focus on its integration into the TSMC COUPE platform for Co-Packaged Optics, a critical component for next-generation AI data center hardware. Community discussion is dominated by bullish sentiment regarding the company's long-term growth narrative in automotive and AI edge-sensing, despite ongoing debates about the timeline for mass adoption and historical stock price volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to reports of impending leadership changes at the FDA, which the community views as a potential catalyst for clearing regulatory hurdles for the companys pipeline. The stock is seeing heightened activity fueled by bullish sentiment regarding ongoing international expansion, institutional accumulation, and a heavily squeezed short interest that investors believe could spark significant upside momentum.

Roundhill ETF Trust - Roundhill Memory ETF

Roundhill Memory ETF ($DRAM) is trending as investors rush to capitalize on the acute global shortage of memory chips, which has positioned DRAM and NAND as critical bottlenecks for AI infrastructure. The community is heavily focused on the ETF's concentrated exposure to memory leaders like SK Hynix, Samsung, and Micron, with bullish sentiment driven by multi-year demand forecasts for high-bandwidth memory.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to positive Phase 3 flu vaccine data and an FDA Fast Track designation for its mRNA-4359 cancer therapy. The community is heavily focused on a potential short squeeze given the significant short interest and the company's broader expansion into oncology and respiratory combination vaccines.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant investor interest as excitement builds around upcoming high-profile IPOs for SpaceX and Anthropic. Community discussions are heavily focused on the fund's direct exposure to these companies, with many participants debating the potential for a share price surge as IPO timelines approach.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

Sui is seeing heavy retail and institutional volume, with the community actively debating whether current price action represents a prime accumulation opportunity or a signal to take profits. Traders are heavily focused on the coin's performance relative to other major L1 chains and are closely watching its ability to hold key technical levels amid high market volatility.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant investor excitement ahead of a highly anticipated conference call regarding interim results for its recurrent glioblastoma (GBM) trial. The community is actively discussing this as a potential binary catalyst and a critical de-risking event for the company's oncology technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiniMed Group (NASDAQ:MMED) Hits New 52-Week Low  - Here's What Happened

MiniMed Group (NASDAQ:MMED) Sets New 1-Year Low - Should You Sell...

MiniMed Group (NASDAQ:MMED) Hits New 1-Year Low  - Should You Sell?

MiniMed Group (NASDAQ:MMED) Sets New 52-Week Low - Here's Why...

MiniMed Group Inc (NASDAQ:MMED) Receives Consensus Recommendation of "Moderate Buy" from Analysts

MiniMed Group Inc (NASDAQ:MMED - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. Two...

MiniMed Group (NASDAQ:MMED) Reaches New 1-Year Low  - Time to Sell?

MiniMed Group (NASDAQ:MMED) Reaches New 1-Year Low - Here's Why...

MiniMed Group (NASDAQ:MMED) Releases Quarterly Earnings Results

MiniMed Group (NASDAQ:MMED - Get Free Report) announced its quarterly earnings results on Friday. The company reported $999.00 EPS for the quarter...

Goldman Sachs' 2 Favorite Under-the-Radar Stocks

Goldman Sachs calls Minimed Group a compelling play on the diabetes market and a potentially profitable stock, with a target price of $24. MiniMed produces insulin pump platforms and continuous...

MiniMed Group (NASDAQ:MMED) Trading Down 5% - Here's Why

MiniMed Group (NASDAQ:MMED) Stock Price Down 5% - Here's Why...

MiniMed to announce financial results for its fourth quarter and full fiscal year 2026

MiniMed to announce financial results for its fourth quarter and full fiscal year 2026 MiniMed to announce financial results for its fourth quarter and full fiscal year 2026 PR Newswire NORTHRIDGE...

MiniMed Group (NASDAQ:MMED) Stock Rating Upgraded by Zacks Research

Zacks Research raised shares of MiniMed Group to a "hold" rating in a research note on Thursday...

MiniMed Group (NASDAQ:MMED) Hits New 1-Year Low - Should You Sell?

MiniMed Group (NASDAQ:MMED) Sets New 1-Year Low - What's Next...

MiniMed Group, Inc. engages in the development, manufacturing, and marketing of a wide range of medical devices and solutions for diabetes management. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets, software platforms, and related accessories that help patients and healthcare providers effectively monitor and control blood glucose levels. The company was founded by Alfred E. Mann in 1983 and is headquartered in Northridge, CA.

MiniMed Group Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$11.57
Prev Close	$11.73
Open	$11.79
Dividend Yield	N/A
50-Day Moving Average	$14.66
Beta	0.00
Avg. Volume	878,880.84
PE Ratio	N/A

52-Week High	$20.48
52-Week Low	$11.25
Market Capitalization	$3.25B
EPS (Annual)	N/A
Price to Book	0.94
Revenue Per Employee	N/A

MMED
MiniMed Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MMED News

MMEDMiniMed Group Inc